In section Market Quotes

Edwards Lifesciences Lifts Annual Forecast After Strong Q3

Surpassing Wall Street expectations, Edwards Lifesciences reported a robust third quarter fueled by a surge in procedure volumes. The medical device manufacturer posted net income of $307.5 million, or 53 cents a share, prompting leadership to elevate its full-year sales growth projections to 12% from previous estimates of 10% to 11%.

By Money Talk·November 5, 2026·2 min read·418 reads

Edwards Lifesciences Lifts Annual Forecast After Strong Q3

Revenue climbed 11% to $1.72 billion during the period, comfortably exceeding analyst projections of $1.68 billion. Adjusted earnings reached 80 cents a share, outperforming the consensus estimate of 74 cents.

Following these results, the company tightened its full-year adjusted earnings guidance to a range of $2.97 to $3.05 per share. The upward revision reflects sustained momentum in core business areas, as healthcare providers continue to see higher demand for the company’s specialized cardiovascular devices.

Edwards Lifesciences Lifts Annual Forecast After Strong Q3

Comments (0)